Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Absci Corporation is a clinical-stage biopharmaceutical company utilizing generative AI to develop innovative therapeutics [1][3] - The company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14th, 2025 [2] Company Overview - Absci's Integrated Drug Creation™ platform combines advanced AI models with a synthetic biology data engine to accelerate drug discovery [3] - The company focuses on creating biologics that address challenging therapeutic targets through a continuous feedback loop between AI algorithms and wet lab validation [3] - Absci is advancing its pipeline of AI-designed therapeutics, including ABS-201™, aimed at treating androgenetic alopecia and potentially serving as a "best-in-class" therapeutic for endometriosis [3] - The company is headquartered in Vancouver, WA, with additional facilities in New York City and Switzerland [3]